Biocon Ltd
NSE:BIOCON
Intrinsic Value
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. [ Read More ]
The intrinsic value of one BIOCON stock under the Base Case scenario is 441.23 INR. Compared to the current market price of 290.5 INR, Biocon Ltd is Undervalued by 34%.
Valuation Backtest
Biocon Ltd
Run backtest to discover the historical profit from buying and selling BIOCON stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biocon Ltd
Current Assets | 140.7B |
Cash & Short-Term Investments | 39.3B |
Receivables | 40.3B |
Other Current Assets | 61.1B |
Non-Current Assets | 405.1B |
Long-Term Investments | 14.3B |
PP&E | 109.2B |
Intangibles | 269.7B |
Other Non-Current Assets | 11.8B |
Current Liabilities | 103.7B |
Accounts Payable | 43.9B |
Other Current Liabilities | 59.7B |
Non-Current Liabilities | 252.3B |
Long-Term Debt | 153.7B |
Other Non-Current Liabilities | 98.6B |
Earnings Waterfall
Biocon Ltd
Revenue
|
146.1B
INR
|
Cost of Revenue
|
-48B
INR
|
Gross Profit
|
98.2B
INR
|
Operating Expenses
|
-79.6B
INR
|
Operating Income
|
18.5B
INR
|
Other Expenses
|
-6.5B
INR
|
Net Income
|
12B
INR
|
Free Cash Flow Analysis
Biocon Ltd
BIOCON Profitability Score
Profitability Due Diligence
Biocon Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Biocon Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
BIOCON Solvency Score
Solvency Due Diligence
Biocon Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Biocon Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOCON Price Targets Summary
Biocon Ltd
According to Wall Street analysts, the average 1-year price target for BIOCON is 287.7 INR with a low forecast of 202 INR and a high forecast of 372.75 INR.
Shareholder Return
BIOCON Price
Biocon Ltd
Average Annual Return | 0.98% |
Standard Deviation of Annual Returns | 39.29% |
Max Drawdown | -59% |
Market Capitalization | 348.8B INR |
Shares Outstanding | 1 200 600 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.
Contact
IPO
Employees
Officers
The intrinsic value of one BIOCON stock under the Base Case scenario is 441.23 INR.
Compared to the current market price of 290.5 INR, Biocon Ltd is Undervalued by 34%.